Alpine Immune Sciences Inc (ALPN)
65.00
+0.04
(+0.06%)
USD |
NASDAQ |
May 17, 16:00
65.00
0.00 (0.00%)
After-Hours: 20:00
Alpine Immune Sciences Cash from Operations (Quarterly): -27.69M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -27.69M |
| December 31, 2023 | -18.97M |
| September 30, 2023 | -15.80M |
| June 30, 2023 | -18.09M |
| March 31, 2023 | -26.15M |
| December 31, 2022 | -16.79M |
| September 30, 2022 | -16.35M |
| June 30, 2022 | -16.07M |
| March 31, 2022 | 5.449M |
| December 31, 2021 | -14.73M |
| September 30, 2021 | 30.13M |
| June 30, 2021 | -14.68M |
| March 31, 2021 | -15.97M |
| December 31, 2020 | -9.349M |
| September 30, 2020 | -5.392M |
| June 30, 2020 | 54.52M |
| March 31, 2020 | -9.694M |
| December 31, 2019 | -5.671M |
| September 30, 2019 | -10.58M |
| June 30, 2019 | -7.877M |
| March 31, 2019 | -11.22M |
| Date | Value |
|---|---|
| December 31, 2018 | -9.398M |
| September 30, 2018 | -7.372M |
| June 30, 2018 | -7.215M |
| March 31, 2018 | -4.431M |
| December 31, 2017 | -5.837M |
| September 30, 2017 | 0.891M |
| June 30, 2017 | -3.19M |
| March 31, 2017 | -8.436M |
| December 31, 2016 | -5.177M |
| September 30, 2016 | -7.524M |
| June 30, 2016 | -6.547M |
| March 31, 2016 | -7.011M |
| December 31, 2015 | -5.401M |
| September 30, 2015 | -5.726M |
| June 30, 2015 | -3.185M |
| March 31, 2015 | -4.895M |
| December 31, 2014 | -3.169M |
| September 30, 2014 | -3.121M |
| June 30, 2014 | -3.522M |
| March 31, 2014 | -4.636M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-27.69M
Minimum
Mar 2024
54.52M
Maximum
Jun 2020
-7.987M
Average
-14.71M
Median
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 1.307B |
| Eliem Therapeutics Inc | -1.819M |
| Regeneron Pharmaceuticals Inc | 1.512B |
| Vera Therapeutics Inc | -33.83M |
| Eyenovia Inc | -9.892M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.562M |
| Cash from Financing (Quarterly) | 19.35M |
| Free Cash Flow | -80.96M |
| Free Cash Flow Per Share (Quarterly) | -0.4327 |
| Free Cash Flow to Equity (Quarterly) | -27.71M |
| Free Cash Flow Yield | -2.30% |